CERo Therapeutics Holdings, Inc. (CERO) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
CERo Therapeutics Holdings, Inc. (CERO) Earnings Overview
As of June 29, 2026, CERo Therapeutics Holdings, Inc. (CERO) reported trailing twelve-month net income of -$21M, reflecting -228.7% year-over-year growth. The company earned $-0.72 per diluted share over the past four quarters.
Looking at the long-term picture, CERO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2,536 in fiscal 2023.
CERo Therapeutics Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), ALLO (-$174M net income), CRSP (-$569M net income, -16569.8% margin), CERO has comparable earnings metrics. Compare CERO vs FATE →
CERO Earnings vs Peers
Earnings metrics vs comparable public companies
CERO Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$20M | -157.6% | -$18M | $-22.58 | - | - |
| 2024 | -$8M | -304789.6% | -$15M | $-6.87 | - | - |
| 2023 | $-2,536 | +99.6% | -$3M | $-2497.20 | - | - |
| 2022 | $-667,736 | -111.6% | -$3M | $-19.73 | - | - |
| 2021 | $-315,547 | - | $-332,030 | $-2.75 | - | - |
Download Data
Export CERO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CERO — Frequently Asked Questions
Quick answers to the most common questions about buying CERO stock.
What is CERO earnings per share (EPS)?
CERO trailing twelve-month (TTM) diluted EPS is $-0.72, reflecting -228.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is CERo Therapeutics Holdings, Inc.'s net income?
CERo Therapeutics Holdings, Inc. (CERO) trailing twelve-month net income is $-21M as of 2025. Earnings declined -228.7% year-over-year.
Is CERO profitable?
CERO is not currently profitable on a TTM basis, reporting a net loss of $-21M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CERO's earnings growth rate?
CERO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are CERO's profit margins?
CERo Therapeutics Holdings, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is CERO growing earnings?
CERO earnings are declining — EPS fell -228.7% year-over-year. TTM net income dropped to $-21M. This contrasts with the 5-year CAGR of N/A.
What was CERO's best earnings year?
CERo Therapeutics Holdings, Inc.'s highest annual net income on record is $-2536.00, achieved in fiscal year 2023. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were CERO's earnings last quarter?
CERO's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.